8-K: Surgery Partners Refinances $1.38B Debt, Cuts Rates

Surgery Partners, Inc. has successfully refinanced its existing term loans and revolving credit commitments, securing new facilities totaling $1.38 billion with reduced interest rates.

Summary

• Refinanced $1,382,500,000 of existing term loans with new 2025 Refinancing Term Loans.
• Refinanced existing revolving credit commitments and outstanding revolving loans with new 2025 Refinancing Revolving Loans.
• The 2025 Refinancing Term Loans mature on December 19, 2030.
• The 2025 Refinancing Revolving Loans mature on December 19, 2028.
• Interest rates for the 2025 Refinancing Term Loans are Term SOFR + 2.50% per annum or an Alternate Base Rate (ABR) + 1.50% per annum.
• Interest rates for the 2025 Refinancing Revolving Loans are Term SOFR + 2.50% per annum or ABR + 1.50% per annum.
• Quarterly amortization payments for the 2025 Refinancing Term Loans will be 0.25% of the aggregate original principal amount, commencing on or around September 30, 2025.
• Voluntary prepayments of the 2025 Refinancing Term Loans are permitted without premium or penalty, except for a 1.00% call premium in the case of certain repricing events occurring prior to the sixth month anniversary of the Second Amendment Effective Date (February 13, 2026).

Sentiment

Score: 8

Explanation: The refinancing significantly reduces borrowing costs and maintains debt maturities, indicating strong financial health and market confidence. The only minor negative is the short-term call premium, which is standard.

Positives

• Reduced interest rate margins on both term loans (25 basis points reduction from Term SOFR + 2.75% to Term SOFR + 2.50%) and revolving credit commitments (75 basis points reduction from Term SOFR + 3.25% to Term SOFR + 2.50%), leading to lower borrowing costs.
• Successfully refinanced a significant debt load of $1.38 billion, indicating strong lender confidence and access to capital markets.
• Maintained existing maturity dates for both term loans (December 19, 2030) and revolving loans (December 19, 2028), avoiding any shortening of debt tenor.

Negatives

• A 1.00% call premium applies to certain repricing events for the 2025 Refinancing Term Loans if they occur within six months of the amendment effective date (before February 13, 2026).

Risks

• Interest rate risk: Loans bear interest at a floating rate (Term SOFR or ABR), exposing the company to potential increases in interest expenses if benchmark rates rise.
• Refinancing risk: While the current refinancing was successful, future refinancing needs could be subject to less favorable market conditions.
• Call premium: Repricing events within the first six months would incur a 1.00% premium, potentially limiting immediate cost-saving opportunities from further rate drops.

Future Outlook

The refinancing provides Surgery Partners with a more favorable debt structure, potentially reducing future interest expenses and enhancing financial flexibility for general corporate purposes, including potential acquisitions and investments.

Management Comments

• David T. Doherty, Executive Vice President and Chief Financial Officer, signed the report on behalf of Surgery Partners, Inc., indicating management's formal approval and execution of the Second Amendment to the Credit Agreement.

Industry Context

This refinancing aligns with a broader trend in the healthcare services industry where companies with strong operational performance seek to optimize their capital structures by taking advantage of favorable credit market conditions, particularly for floating-rate debt. Lower interest costs can free up capital for strategic investments or operational improvements.

Comparison to Industry Standards

• The 25 basis point reduction in Term SOFR margin for term loans (from 2.75% to 2.50%) and 75 basis point reduction for revolving loans (from 3.25% to 2.50%) suggests that the company was able to secure terms better than or in line with current market conditions for well-performing healthcare providers, especially given the current interest rate environment.
• The 0.25% quarterly amortization for term loans is a standard industry practice for syndicated term loan B facilities, indicating a typical repayment schedule.
• The 6-month 1.00% soft call protection is also a common feature in syndicated loan markets, protecting lenders from immediate repricing risk post-refinancing.

Stakeholder Impact

• Shareholders: Potential for increased profitability due to lower interest expenses, which could positively impact earnings per share.
• Creditors/Lenders: The refinancing indicates continued confidence in the company's ability to manage its debt and operations, providing a stable investment.
• Employees/Customers/Suppliers: Improved financial flexibility may support continued business operations, investments, and stability.

Next Steps

• Amortization payments for the 2025 Refinancing Term Loans will commence on or around September 30, 2025.
• The company will continue to operate under the amended credit agreement, utilizing the refinanced facilities for general corporate purposes, including potential acquisitions and investments.

Key Dates

Recommendation

The successful refinancing at significantly lower interest rates, coupled with the maintenance of existing debt maturities, demonstrates strong financial management and market confidence in Surgery Partners. This reduction in borrowing costs is a direct positive to the company's profitability and cash flow, making the stock more attractive for investment. The company's ability to secure such favorable terms in the current market environment suggests a robust underlying business and a positive outlook for future performance.

Keywords

Surgery Partners, SGRY, Credit Agreement, Debt Refinancing, Term Loans, Revolving Credit, Interest Rates, SOFR, Healthcare Services, Financial Management, SEC Filing